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A simple high performance thin layer chromatography (HPTLC) has been developed and validated 
for determination of sunitinib malate and possible impurities. The samples were applied in forms of 
bands on an aluminum TLC plate pre-coated with silica gel and were separated using dichloromethane: 
methanol: toluene: ammonia solution as the mobile phase. Sunitinib malate was thoroughly separated 
from impurities including E-isomer, sunitinib N-oxide and impurity B with a retention factor (RF) of 
0.35±0.02. Quantitative analysis of sunitinib was carried out using a mobile phase consisting of dichlor
omethane:methanol:ammonia solution, RF value was 0.53±0.02 for Z isomer. Detection was performed 
densitometrically in absorbance mode at  430 nm. This method was found to produce sharp, symmetrical, 
and well resolved peaks. Linear relationship with the coefficients of determination > 0.99 was achieved 
over the concentration range of 27.34 to 437.5 ng/spot. This method provides robust, replicable and 
accurate results with acceptable sensitivity.  
Uniterms:  Sunitinib malate/quantitative analysis. High Performance Thin Layer Chromatography/
method/validation. Sunitinib malate/E-Z isomer.
INTRODUCTION
Sunitinib malate, N-(2-diethylaminoethyl)-5-
[(Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl]-2,4-
dimethyl-1H-pyrrole-3-carboxamide, is an oral anticancer 
drug, which is marketed under the trade name Sutent® 
by Pfizer, Inc., New York. The chemical structure of 
sunitinib malate is shown in Figure 1. This drug is a novel 
multitargeted tyrosine kinase inhibitor with antitumor and 
antiangiogenic activities for the treatment of renal cell 
carcinoma (RCC) and imatinib-resistant gastrointestinal 
stromal tumor (GIST) (Kessler et al., 2007).
A very important stage in the process of production 
and development of pharmaceuticals is the analysis of 
components present in bulk drugs and their formula tions 
in order to ensure that pharmaceutical products are of 
the quality required for their intended use. Accordingly 
so far, a few analytical methods have been established 
for the determination and quantitative analysis of 
sunitinib malate, which are mainly based on High 
Performance Liquid Chromatography (HPLC) method 
(Rizwana, Prakash, Mohan, 2014; Sandhya et al., 2011). 
Furthermore, many methods mostly based on LC/MS have 
been presented in order to monitor drugs in biological 
fluids such as plasma (Oberoi, Mittapalli, Fisher, 2013; 
FIGURE 1 - Chemical structure of sunitinib malate.
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Etienne Grimaldi et al., 2009; Minkin et al., 2008; 
De Bruijin et al., 2010). However, to the best of our 
knowledge, there is no published analytical method for 
detection and quantification of sunitinib malate based on 
thin layer chromatography (TLC/HPTLC). 
Thin layer chromatography is a chromatography 
technique used to separate and analyze mixtures using 
a thin stationary phase supported by an inert backing. 
From the mid-1970s, with the introduction of modern 
methodological and instrumental advances made in 
TLC (called high performance TLC), the application of 
this method in qualitative and quantitative analysis of 
pharmaceutical, environmental, toxicological, food, and 
agricultural samples has increasingly grown (Sherma, 
2010; Sherma, 2000, 2009; Le Roux et al., 1992; Rakesh 
et al., 2013). This trend continued so that nowadays in 
some quality control laboratories quantitative HPTLC 
is routinely used (Ferenczi-Fodor, Renger, Veigh, 2010).
The main advantages of HPTLC are as follows: 
simplicity of procedure, minimal pretreatment, efficiency 
with small amounts of sample, parallel analysis of samples 
(a 20×10 cm plate can contain up to 72 samples, which can 
be analyzed simultaneously and under identical conditions), 
multiple nondestructive methods for detection (for example 
visualization and scan in visible or UV light at different 
wavelengths), numerous options  for developing solvents, 
low consumption of solvents, time and cost effectiveness 
(In fact, the expenses associated with providing solvents 
and maintenance are much lower in comparison with 
HPLC.) These advantages along with reliability, sen sitivity, 
and reproducibility enable this method to be an important 
alternative to other chromatographic techniques such as 
HPLC. As an instance, the results of a study indicated that 
while the precision and accuracy of HPLC and HPTLC 
methods of phospholipids can be comparable, HPTLC was 
more cost-effective than HPLC (Renger,1999). 
In recent years, numerous publications have 
been devoted to the application of HPTLC methods in 
pharmaceutical analysis (Sherma, 2010; Askal et al., 
2008; Kadam, Bari, 2007; Mhaske, Dhaneshwar, 2007). 
For example, the following cases can be mentioned: 
determination of amantadine, an antiviral drug, in 
pharmaceu tical formulations (Askal et al., 2008), 
simultaneous analysis of valsartan and hydrochlorothiazide, 
an antihypertensive drug, in tablet formulation (Kadam, 
Bari, 2007), determination of omeprazole, a proton pump 
inhibitor, in capsule form (Jha et al., 2010), simultaneous 
quantitation of paracetamol, diclofenac potassium, and 
famotidine in tablet formulation (Khatal et al., 2010), 
determination of  imatinib (Vadera, Subramanian, 
Musmade, 2007) and dasatinib (Mhaske, Dhaneshwar, 
2007) as anticancer medicines in pharmaceutical form.
The present study describes a simple and viable 
analytical method for identification and quantitative 
analysis of sunitinib malate in bulk drug employing 
HPTLC-densitometric technique. The proposed method 
was developed and validated based on ICH guidelines.
MATERIAL AND METHODS
Material
Sunitinib malate salt was obtained from chemistry 
department at TODA Research & Engineering Company, 
Iran and was used without any purification. Standard of 
E and Z isomer mixture, sunitinib malate N-oxide and 
impurity B was purchased from TLC PharmaChem Inc., 
Canada. HPLC-grade methanol, dichloromethane, acetic 
acid, toluene, and ammonium hydroxide (25%) were 
purchased from Merck, Germany. All dilute solutions of 
ammonium hydroxide were prepared from demineralized 
water with a specific conductance equal to 1.2±0.1 μScm−1. 
Instrumentation
An automatic sample applicator (Camag Linomat 
IV, Switzerland) equipped with a Hamilton 100-μL syringe 
was employed for samples application on the HPTLC plate. 
Chromatographic separations were performed on 20×20 cm 
aluminum backed plates pre-coated with 0.2 mm layers of 
silica gel and fluorescent indicator with a 254 nm excitation 
wavelength (Kieselguhr 60F-254, E. Merck, Germany). 
A Camag twin-trough chamber for 20×20 cm plates, with 
a stainless steel lid, was used for ascending development 
of the plates. Densitometric scanning was performed on 
Camag TLC scanner II, operated with CATS3 software 
while the source of radiation was a tungsten lamp. 
HPTLC analysis
Pre-condi t ion ing:  Af te r  se lec t ion  o f  the 
chromatographic layer, plates were prewashed with 
methanol, and were then activated at 70 °C for 60 min. 
Sample application: By means of an automatic 
applicator the samples were spotted with a constant 
application rate of 5 s/µL in the form of bands of 6 mm in 
width. The space between bands was 4 mm. The distance 
from the left edge and the bottom of the plate was kept at 
30 and 20 mm respectively. 
Selection of suitable mobile phase: The following 
solvent mixtures were selected as candidates for the 
method development: dichloromethane: methanol, 
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dichloromethane: methanol: acetic acid, dichloromethane: 
methanol: ammonia 25%-5%), dichloromethane: 
methanol: triethylamine, and dichloromethane:methan
ol:toluene:ammonia. Different compositions of above 
mentioned solvents were tested taking into account their 
polarities in order to select the optimized mobile phase for 
separation of sunitinib malate.
Chromatographic development: The tank was 
saturated for 15 min before insertion of the spotted plate. 
Plates were developed with 20 mL of mobile phase in strict 
light-protected conditions. The development distance was 
approximately 100 mm. The chromatography was run at 
25 °C± 3 and at relative humidity of 33%± 3.
Detection and scanning: After development, the 
plate was dried in open air for 5 min. Densitometric 
scanning was then performed in the absorbance mode and 
at the speed of 4 mm/s, using the tungsten light source 
at 430 nm (λmax for the compounds). Monochromator 
bandwidth was kept at 30 nm and the dimension of slit 
was set at 5 mm in length and 2 mm in width.
Preparation of stock and working solutions
A stock solution was prepared (500 µg/mL) 
by dissolving and diluting 5 mg of sunitinib malate 
(MM=532.561 g/mol ) to 10 mL with methanol in light-
protected conditions. The solution was sonicated for 15 
minutes. Working solutions of sunitinib malate were 
prepared in amber colored glass vials by further dilution 
of the stock with methanol in a concentration range of 
3.91 to 250 µg/mL. 
Calibration curve 
The amount of 7 µl of each working solutions (3.91 
to 250 µg/mL), equivalent to 27.3, 54.6, 109.3, 218.7, 
291.6, 437.5, 875.0 and 1750.0 ng per spot of sunitinib 
malate, were applied in three replicates on the TLC 
plate. The spotted plates were developed and scanned 
as described above. Calibration curve was constructed 
by plotting average peak areas versus the corresponding 
amounts and regression equation was calculated for 
sunitinib malate.
RESULTS AND DISCUSSION 
Method Development and Optimization
Various chromatographic condit ions were 
investigated to attain satisfactory results of sunitinib 
malate qualitative and quantitative analysis. Developing 
the mobile phase individually on glass and aluminum TLC 
plate and comparing results indicated that using aluminum 
backing plates produces well defined spots with better 
resolution. Hence, in this work, aluminum sheet plates 
precoated with silica gel were selected as stationary phase. 
In order to achieve the optimal mobile phase which 
enables the separation of sunitinb malate and any possible 
impurities, different compositions and ratios of solvents 
with various polarities were tested. For instance, a number 
of solvent systems applied in this study are listed in Table I. 
The most important impurities in this study were 
E isomer of sunitinib, sunitinib N-oxide (C22H27FN4O3), 
TABLE I - Different kinds of solvent mixtures which are tested in this study along with RF values
Mobile phase Volume ratio (v:v)
RF values
Z-isomer E-isomer N-oxide Impurity B
ethyl acetate: toluene: acetic acid 5:3:2 0 0 0 0
dichloromethane: methanol 9:1 0.6 0.56 0.6 1
5:1 0.43 0.40 0.5 1
3:1 0.32 0.22 0.30 1
1:1 0.29 0.29 0.29 1
dichloromethane: methanol:acetic acid 3:1:0.05 0.41 0.33 0.51 1
dichloromethane: methanol:NH3(25%) 3:1:0.1 0.37 0.37 0.39 1
dichloromethane: methanol: NH3(8%) 3:1:0.05 0.40 0.31 0.41 1
dichloromethane: methanol:NH3(5%) 3:1:0.1 0.53 0.42 0.64 1
dichloromethane: methanol: 
toluene:NH3(5%)
3:1.5:0.5:0.05 0.35 0.25 0.47 0.94
dichloromethane: methanol: 
toluene:NH3(5%)
3:1:1:0.05 0.43 0.36 0.46 0.86
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and impurity B (C20H20FN3O2). Due to the presence of 
a double bond between 2-oxindol and the pyrrole ring, 
sunitinib has two stereoisomeric forms: the  E and Z 
isomers (Honeywell et al., 2010). Although Z isomer is 
the thermodynamically stable form, it can convert to E 
isomer when it is introduced into the solution exposed 
to light. Also, some studies have demonstrated that E 
isomer can convert to Z isomer when sunitinib malate 
was placed in the dark. Only Z isomer of sunitinib 
is a drug substance while E isomer is inactive and 
unstable. Hence, all experiments were done in light-
protected conditions. However the Z-to-E isomerism of 
sunitinib could not be completely avoided. The results 
of trials showed that among the solvents which were 
tested a combination of dichloromethane and methanol 
with volume ratio of 3:1 perfectly separated the two 
stereoisomeric forms of sunitinib malate, so that E isomer 
appears (as a small peak) before Z isomer (desired drug 
substance) and produces sharp and symmetrical peaks 
without tailing. However, using this solvent system led 
to an overlap between the peak of sunitinib N-oxide and 
Z isomer. Hence, in another trial, ammonium hydroxide 
solution with different volume ratios (25% to 5%) was 
added to the above system. It was found that addition 
of 0.1 ml diluted ammonium hydroxide to 5% can 
completely separate main drug substance from E isomer 
and sunitinib N-oxide impurity. Under established 
conditions, quantitative analysis of sunitinib malate 
was carried out and the retention factor (Rf) value for 
Z-isomer of sunitinib was obtained, 0.53±0.02 (Figure 
2). Nevertheless, as the solvent system mentioned above 
develops, impurity B appears on the solvent front and 
hence could not be properly detected. After several trials, 
it was found that decreasing polarities of the mentioned 
solvent system by adding 0.5 mL of toluene leads to the 
separation of all considered components with satisfactory 
Rf values (Figure 3). Furthermore, the results showed that 
the saturation of chamber with mobile phase vapors for 
15 min at room temperature before the development of 
the plate improves the spot characteristic. 
Also, the optimum wavelength was determined to 
be 430 nm after scanning the developed plate from 400 
nm to 700 nm using the tungsten lamp.
METHOD VALIDATION
The developed method was validated by linearity, 
accuracy, precision, robustness, limit of detection (LOD) 
and limit of quantitation (LOQ) according to the ICH 
guidelines. These will be discussed separately in the 
following sections. 
FIGURE 2 - A typical HPTLC chromatogram of sunitinib malate.
FIGURE 3 - Separation of Z isomer of sunitinib from related 
impurities using dichloromethane: methanol: toluene:NH3(5%) 
with volume ratio of 3:1.5:0.5:0.05.
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LINEARITY
To evaluate linearity range, the calibration curve 
(n=3) was plotted based on the peak area response versus 
sunitinib malate amount and was treated by linear least 
square regression (Figure 4).  The results as presented 
in Table 2 showed a good linear relationship (R2=0.997) 
over the concentration range 27.34- 437.5 ng per spot with 
respect to peak area. 
Precision
The precision was estimated at three different 
concentration levels of 54.69, 218.75, and 291.67 ng 
per spot to evaluate three sources of variation. At first, 
precision was assessed when the same spot is measured 
three times by densitometer. Secondly, the same solution 
is spotted three times, and finally overall repeatability 
was evaluated when the analysis was carried out in the 
same conditions by the same analyst during two different 
days. The results presented as relative standard devia tion 
percentage (%RSD) depicted in Table III. The obtained 
RSD values were less than 3%, which confirms the good 
repeatability of sample application and measurement of 
peak area as well as acceptable intermediate precision. 
In TLC densitometry, RSD value in range of 1%–5% is 
acceptable (Komsta et al., 2013).
Sensitivity
The sensitivity of measurement was estimated as 
the limits of quantification (LOQ) and detection (LOD), 
which were expressed based on the standard deviation of 
the intercept and the slope of the linearity plot as described 
in the related ICH guideline. The LOD and LOQ are 
calculated by exploiting the equations 3.3 α/b and 10 
α/b, where α is the standard deviation of the intercept 
and b is the slope of the corresponding calibration plot. 
Accordingly, the values of LOD and LOQ for sunitinib 
malate were found to be 23.26  and 70.50 ng per spot 
respectively, as it is displayed in Table IV below.
Accuracy
The accuracy of the method was evaluated by 
analyzing samples of sunitinib malate with triplicate 
spotting at two levels of concentration, namely 72.92 
and 291.67 ng per spot. After the development of the 
plate, percent recoveries were calculated from the slope 
and intercept of the calibration plot was achieved from 
the linearity study. The results obtained were compared 
with the expected results. As it can be seen in Table 
IV, the percent recoveries are within the acceptable 
range of 90–110%, which confirms the accuracy of the 
developed method, data for recoveries is presented below 
(Table V). 
TABLE II - Linear regression data for the calibration curvea
 
Parameters Amounts
Linearity range 27.34 - 437.50  ng per spot
R² 0.997
slope 4.0191
Intercept 78.5292
a n=3
TABLE III - Precision data for sunitinib malatea
  
Parameters S.D. %RSD
mea surement precision 7.88 0.75
spotting precision 13.88 1.56
intermediate precision 39.38 2.63
a Average of three concentrations 54.688, 218.750, 291.667 ng 
per spot (n=3)
FIGURE 4 - Calibration curve for sunitinib malate.
TABLE IV - LOD and LOQ values
   
Slope
Standard 
deviation of 
y-intercept
LOD 
(ng spot-1)
LOQ 
(ng spot-1)
4.019 28.33 23.26 70.50
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Robustness
According to its definition, robustness is “a measure 
for the susceptibility of a method to small changes 
that might occur during routine analysis” (Komsta, 
Waksmundzka-Hajnos, Sherma, 2013). Hence, in this 
work, the effects of applying slight changes in the time 
intervals between chromatography and scanning, as 
well as the amount of mobile phase from 16 mL to 20 
mL, were studied. The standard deviation of peak areas 
was calculated for each parameter at three different 
concentration levels of 54.69, 218.75, 291.67 ng per spot 
while %R.S.D. was found to be less than the acceptable 
value of 5%, which indicates the robustness of the method. 
CONCLUSION 
A new HPTLC densitometric method was developed 
for the analysis of sunitinib malate in bulk drug and was 
validated in accordance with the requirements of ICH 
guidelines and proved to be repeatable, precise, accurate 
and robust. The procedure is simple, rapid and inexpensive 
in comparison with other analytical methods and, at the 
same time, reasonably viable in order to be suggested for 
the routine analysis of sunitinib malate.  
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